Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology. For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1%. Please find the ...
Ackermans & van Haaren soutient le tour de financement de série B de 55 millions d’euros de MRM Health Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren (AvH) soutient le tour de financement de Série B totalisant 55 millions d’euros de MRM Health, une société biopharmaceutique en phase clinique, pionnière dans les thérapeutiques basées sur le microbiome pour les maladies inflammatoires et l’immuno-oncologie. Pour AvH, ce tour de financement de Série B comprend un investissement supplémentaire de 3 millions d'euros, ce qui porte l'investissement total d'AvH dans MRM Health à 10...
Ackermans & van Haaren ondersteunt de serie B-financieringsronde van 55 miljoen euro van MRM Health Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren (AvH) ondersteunt de serie B-financieringsronde van in totaal 55 miljoen euro van MRM Health, een biofarmaceutisch bedrijf in de klinische fase dat pioniert met therapieën op basis van het microbioom voor inflammatoire aandoeningen en immuun-oncologie. Voor AvH omvat deze serie B-financieringsronde een aanvullende investering van 3 miljoen euro, waarmee de totale investering van AvH in MRM Health op 10,8 miljoen...
In this note we update our Sum-of-the-Parts valuation model after the 1H25 results publication and related analyst meeting. This note summarises the key topics from the release and updates our earnings forecasts. Last week's release was a clear illustration of Ackermans & van Haaren's (AvH) successful strategy of focusing on a limited number of assets in different sectors of growth that are jointly creating a regular stream of revenues as the main driver for value creation for the group. We have...
Ackermans & van Haaren s’engage à hauteur de 20 millions de dollars dans le deuxième fonds de Venturi Partners Cher actionnaire, Monsieur, Madame, veuillez trouver ci-joint notre communiqué. Meilleures salutations, Ackermans & van Haaren Pièce jointe
Ackermans & van Haaren investeert 20 miljoen US dollar in het tweede fonds van Venturi Partners Geachte aandeelhouder, Geachte mevrouw, geachte heer, gelieve bijgevoegd ons persbericht te vinden. Met vriendelijke groeten, Ackermans & van Haaren Bijlage
Ackermans & van Haaren: A strong 1H25. Avantium: Nearly there. Eurocommercial Properties: Good results, positive effects of remerchandising. Recticel: Weak 1H25 calls for a 12% downgrade to consensus at Adj. EBITDA level. Sif Group: 2025 and 2026 guidance cuts. Staffing: Belgium - July Temp volume weaker at -3.5% YoY despite easier comps
Ackermans & van Haaren: First-Half 2025 Results Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren publishes today its Half-Year 2025 Results Strong results of core participations support the growth of Ackermans & van Haaren’s H1 2025 profit to 273 million euros (+36%) Record half-year results at DEME, Delen Private Bank, Bank Van Breda and SIPEFSignificant improvement of results at NextensaOutlook (strengthened): net profit for the full-year 2025 is expected to increase by at least 15%Positive net cash position of 431 million euros Please find annexed the full press rel...
Ackermans & van Haaren : Résultats semestriels 2025 Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren publie aujourd'hui ses résultats semestriels pour 2025 Les bons résultats des participations principales soutiennent la croissance du bénéfice d’Ackermans & van Haaren pour le premier semestre 2025, qui atteint 273 millions d’euros (+36%) Des résultats record au premier semestre chez DEME, Delen Private Bank, la Banque Van Breda et SIPEFAmélioration significative des résultats de NextensaPerspectives (relevées): le bénéfice net pour l’ensemble de l’exercice 2025 devrait croît...
Ackermans & van Haaren: Halfjaarresultaten 2025 Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren publiceert zijn halfjaarresultaten 2025: Sterke resultaten van de kernparticipaties steunen de winstgroei van Ackermans & van Haaren in eerste helft 2025 naar 273 miljoen euro (+36%) Record halfjaarresultaten bij DEME, Delen Private Bank, Bank Van Breda en SIPEFAanzienlijke verbetering van de resultaten van NextensaVooruitzichten (versterkt): de nettowinst voor 2025 zal naar verwachting met meer dan 15% stijgenPositieve nettokaspositie van € 431 miljoen Gelieve...
Ackermans & van Haaren: Expect buoyed contribution from Private Banking. ASR: 1H: strong solvency, buyouts at 12% IRR. Deceuninck: Weak set of results, as expected following the change in CEO. EVS: Very weak 1H25, but guidance unchanged; convincing bolt-on deal in the US. IBA: IBA to install one P1 system at university campus in Heidelberg, Germany. NEPI Rockcastle: Robust performance, small upward revision to guidance
1M Performance - Absolute Total Return: During Jul'25 (1M period), the KBCS Holdings Universe posted a total return of -0.5% which was mainly driven by the performance of the multi-asset holdings (-0.9%), while the single-asset holdings posted a return of +0.4%. The 3 top performers during the period were Financière de Tubize (+11.7%), KBC Ancora (+9.4%) and Quest For Growth (+5.5%) while the 3 worst performers were Brederode (-6.4%), Heineken Holding (-5.0%) and D'Ieteren Group (-4.7%). YTD Pe...
We downgrade our recommendation for Ackermans & van Haaren (AvH) from Buy to HOLD. The share price has had a strong run, pricing in the higher valuation of the banks, while the fair value for all other segments within AvH's portfolio on balance have remained unchanged. Therefore, given the 10% forecast total return to the current share price, we fail to see a short term catalyst to push the valuation higher and the stock is currently trading at a FY25F P/E of 13.9x, only slightly below the 10-ye...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.